A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)

Study Overview
=================
Brief Summary
-----------------
A phase IIa study to evaluate the pharmacokinetic and efficacy of amonafide L-malate (AS1413) in combination with cytarabine in treating patients with acute myeloid leukemia (AML)

Official Title
-----------------
A Phase IIa Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Adult Patients With Acute Myeloid Leukemia (AML)

Conditions
-----------------
Acute Myeloid Leukemia

Intervention / Treatment
-----------------
* Drug: Amonafide + cytarabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing and able to provide written informed consent In the opinion of the Investigator able to comply with the study assessments and follow-up New diagnosis of AML (i.e. >20 % blasts) as defined by the World Health Organization (WHO) classification (Vardiman 2009) or relapsed or refractory AML as defined by the persistence or recurrence of >5% blasts in bone marrow or peripheral blood following treatment. ECOG Performance status ≤ 2 Age > 18 years and ≤ 70 years Adequate hepatic function as evidenced by the following laboratory tests: Total serum bilirubin ≤ 1.5 x ULN or direct (conjugated) bilirubin ≤ 1.5 ULN unless attributable to suspected hepatic involvement with AML Serum AST and ALT ≤ 1.5 x ULN unless attributable to suspected hepatic involvement with AML Adequate renal function as evidenced by serum creatinine ≤ 1.5 x ULN Women of childbearing potential must have a negative serum pregnancy test. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. This includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives Left Ventricular Ejection Fraction (LVEF) > 50%, as determined by multiplegated acquisition scan (MUGA) or echocardiogram (ECHO) within 28 days prior to administration of 1st dose of remission induction chemotherapy Exclusion Criteria: Unwilling to accept the required per protocol blood and urine sample collection An initial diagnosis of acute promyelocytic leukemia as defined by French- American-British criteria (Bennett 1976) (otherwise known as FAB M3) Clinically active CNS leukemia History of clinically significant allergic reactions attributed to compounds of similar chemical or biological composition to amonafide or cytarabine Pregnant or breast feeding Known HIV positive Known active hepatitis B or C, or any other active liver disease Evidence of pulmonary infection. Patients with evidence of pulmonary infection on screening chest x-ray should have chest computed tomography (CT) prior to starting remission induction therapy to confirm absence or presence of pulmonary infection. Any major surgery or radiation therapy within 30 days prior to study entry Previously received treatment with amonafide Treatment with other investigational agents for any reason within 30 days prior to study entry Prior remission induction therapy for AML within 30 days of starting amonafide therapy Persistent non-hematologic toxicity (other than alopecia) greater than Grade 2 from prior therapy for MDS or AML Serious concomitant illnesses (for example, unstable angina or myocardial infarction or stroke within 3 months prior to study entry, congestive heart

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Single-arm<br>Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7 | Drug: Amonafide + cytarabine<br>* Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To define the plasma PK Profile of amonafide and metabolite(s) |  | 1 year | 
| To deine the urniary excretion of amonafide and metabolite(s) |  | 1 year | 
| To investigate the fecal excretion of amonafide and metabolite(s) in selected patients |  | 1 year | 
| To evaluate the safety and tolerability of amonafide in combination with cytarabine |  | 1 year | 
| To evaluate the remission rate |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All outcomes are of equal weighting |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AML, Pgp, MDR, sAML, AS1413, Amonafide